AN ACT to amend Tennessee Code Annotated, Title 4; Title 29; Title 36; Title 63 and Title 68, relative to assisted reproductive technology.
SB2461 creates a new regulatory framework for fertility clinics that provide assisted reproductive technology (ART) services in Tennessee. The bill defines key terms such as ART, fertility clinic, and the Society for Assisted Reproductive Technology (SART), and requires each fertility clinic operating in the state to obtain a certificate from the Department of Health in order to perform ART services. To receive and renew certification, a clinic must show SART membership or an approved equivalent, provide an emergency plan for embryo transfer if the clinic closes, and prove successful passage of the most recent laboratory inspection by an approved accrediting body.
The bill also sets minimum qualifications for clinical directors, requiring licensure in medicine or osteopathic medicine, board certification in obstetrics and gynecology, completion of a reproductive endocrinology and infertility fellowship or equivalent training and experience, substantial ART experience, and continuing medical education in the field. In addition, it directs fertility clinics to follow current evidence-based professional standards for genetic testing, while expressly stating that this requirement does not create a private right of action, a specific legal standard of care, or liability. The Department of Health is authorized to adopt rules to implement the new part, and the act takes effect in stages, with rulemaking effective upon enactment and the rest effective January 1, 2027.
The bill amends Tennessee Code Annotated by adding a new part to Title 68 governing assisted reproductive technology clinics and related services. It creates a state certification requirement for fertility clinics, establishes licensing and qualification standards for clinical directors, and gives the Department of Health oversight and rulemaking authority. The measure affects fertility clinics, embryo laboratories, ART providers, and patients seeking fertility treatment, while also referencing federal ART definitions and recognized national accreditation and professional organizations.
The bill appears to have been generally favorable and broadly supported, as reflected by strong committee and floor votes, including unanimous or near-unanimous concurrence votes and passage with substantial margins. The legislative findings and structure of the bill suggest an emphasis on patient safety, clinic quality, and standardized oversight of fertility services. The absence of committee transcript material limits insight into detailed debate, but the voting history indicates overall bipartisan acceptance of the measure.
The main points of potential contention are the new state certification requirement, the reliance on SART membership or an equivalent organization approved by the Department of Health, and the professional qualifications imposed on clinical directors. These provisions could be viewed as increasing regulatory burdens on fertility clinics or narrowing who may operate such facilities. The genetic testing section may also have drawn attention because it requires adherence to professional guidelines while explicitly disclaiming a private cause of action or a fixed standard of care, suggesting an effort to regulate practice without creating new liability exposure.